Phase I/II Trial of EXL01 to Prevent Clostridioides Difficile Infection Recurrence
A Phase I/II trial is evaluating the efficacy and safety of EXL01, an isolated strain of F. prausnitzii, for preventing CDI recurrence in high-risk patients.
Therapeutic Area
Therapeutic area intelligence for Clostridioides Difficile Infection with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.